ALK and non-small cell lung carcinoma: In 2018, a double-blind, phase 3 trial in patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, addition of pembrolizumab to standard chemotherapy with pemetrexed and a platinum-based drug, compared to chemotherapy alone, resulted in significantly longer overall survival and progression-free survival [5].